NASDAQ:CDXC

ChromaDex Stock Forecast, Price & News

$9.14
+0.20 (+2.24 %)
(As of 06/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.29
$9.42
50-Day Range
$6.66
$10.54
52-Week Range
$3.82
$23.66
Volume1.67 million shs
Average Volume2.29 million shs
Market Capitalization$620.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68
30 days | 90 days | 365 days | Advanced Chart
Receive CDXC News and Ratings via Email

Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter.


ChromaDex logo

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

625th out of 2,106 stocks

Medicinals & Botanicals Industry

3rd out of 32 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ChromaDex (NASDAQ:CDXC) Frequently Asked Questions

Is ChromaDex a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ChromaDex stock.
View analyst ratings for ChromaDex
or view top-rated stocks.

What stocks does MarketBeat like better than ChromaDex?

Wall Street analysts have given ChromaDex a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ChromaDex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ChromaDex's next earnings date?

ChromaDex is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for ChromaDex
.

How were ChromaDex's earnings last quarter?

ChromaDex Co. (NASDAQ:CDXC) announced its quarterly earnings data on Thursday, May, 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.03. The company earned $14.68 million during the quarter, compared to analysts' expectations of $16.47 million. ChromaDex had a negative trailing twelve-month return on equity of 84.50% and a negative net margin of 35.92%.
View ChromaDex's earnings history
.

How has ChromaDex's stock price been impacted by Coronavirus?

ChromaDex's stock was trading at $3.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CDXC shares have increased by 148.4% and is now trading at $9.14.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CDXC?

3 analysts have issued twelve-month price targets for ChromaDex's stock. Their forecasts range from $9.00 to $18.00. On average, they expect ChromaDex's stock price to reach $12.67 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price.
View analysts' price targets for ChromaDex
or view top-rated stocks among Wall Street analysts.

Who are ChromaDex's key executives?

ChromaDex's management team includes the following people:
  • Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 53, Pay $592.42k)
  • Mr. Robert N. Fried, CEO & Director (Age 61, Pay $810.27k)
  • Mr. Kevin M. Farr, Chief Financial Officer (Age 63, Pay $479.6k)
  • Mr. Ben Shichman, Chief Technology Officer
  • Dr. Andrew Shao Ph.D., Sr. VP of Global Regulatory & Scientific Affairs
  • Brianna Gerber, VP of FP&A and Investor Relations
  • Ms. Lisa Hatton Harrington, Gen. Counsel & Corp. Sec. (Age 53)
  • Alex Worsham, VP of Global Marketing & Communications
  • Mr. Frank M. Fazio, Sr. VP of Global Bus. Devel. & Sales (Age 52)
  • Mr. Fadi Karam, Chief Marketing Officer

What is Robert Fried's approval rating as ChromaDex's CEO?

10 employees have rated ChromaDex CEO Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among ChromaDex's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ChromaDex's key competitors?

What other stocks do shareholders of ChromaDex own?

What is ChromaDex's stock symbol?

ChromaDex trades on the NASDAQ under the ticker symbol "CDXC."

Who are ChromaDex's major shareholders?

ChromaDex's stock is owned by many different institutional and retail investors. Top institutional shareholders include Yong Rong HK Asset Management Ltd (6.08%), BlackRock Inc. (4.67%), ICONIQ Capital LLC (1.91%), Millennium Management LLC (1.34%), Geode Capital Management LLC (1.08%) and Uniplan Investment Counsel Inc. (0.99%). Company insiders that own ChromaDex stock include Frank L Jaksch Jr, Kevin M Farr, Robert N Fried and Stephen A Block.
View institutional ownership trends for ChromaDex
.

Which institutional investors are selling ChromaDex stock?

CDXC stock was sold by a variety of institutional investors in the last quarter, including Tieton Capital Management LLC, Uniplan Investment Counsel Inc., ICONIQ Capital LLC, Morgan Stanley, JPMorgan Chase & Co., UBS Group AG, AQR Capital Management LLC, and Kestra Advisory Services LLC. Company insiders that have sold ChromaDex company stock in the last year include Frank L Jaksch Jr, and Stephen A Block.
View insider buying and selling activity for ChromaDex
or view top insider-selling stocks.

Which institutional investors are buying ChromaDex stock?

CDXC stock was purchased by a variety of institutional investors in the last quarter, including Yong Rong HK Asset Management Ltd, Millennium Management LLC, Goldman Sachs Group Inc., BlackRock Inc., Canada Pension Plan Investment Board, PEAK6 Investments LLC, Geode Capital Management LLC, and Belvedere Trading LLC. Company insiders that have bought ChromaDex stock in the last two years include Kevin M Farr, and Robert N Fried.
View insider buying and selling activity for ChromaDex
or or view top insider-buying stocks.

How do I buy shares of ChromaDex?

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChromaDex's stock price today?

One share of CDXC stock can currently be purchased for approximately $9.14.

How much money does ChromaDex make?

ChromaDex has a market capitalization of $620.91 million and generates $59.26 million in revenue each year. The company earns $-19,920,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does ChromaDex have?

ChromaDex employs 110 workers across the globe.

What is ChromaDex's official website?

The official website for ChromaDex is www.chromadex.com.

Where are ChromaDex's headquarters?

ChromaDex is headquartered at 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024.

How can I contact ChromaDex?

ChromaDex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected]


This page was last updated on 6/25/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.